PhD project

Lærke Rosenlund Nielsen, MSc

Publications (link to AU profile)

The project focuses on the use of circulating tumor DNA for detection of minimal residual disease after curative-intent treatment. All patients included in the study have been diagnosed with Early-stage or locally advanced-stage non-small cell lung cancer and have received treatment with curative intent. Blood samples taken before and after treatment are analyzed with Next-Generation sequencing. The aim is to investigate whether circulating tumor DNA can be used as a biomarker to predict which patients will relapse after curative-intent treatment and thus identify which patients may benefit from consolidation treatment. In addition, it will also be investigated what significance the timepoint of collecting the blood sample after treatment may have on the result.